indication

Bipolar Disorder

Competitive landscape

as of 2026-07-01
Competitive set
12
11 approved · 1 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
66 events
2020
2024
2028
2032
2036
2040
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugRecruiting
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 412 trials
OwnerEli Lilly and Company
Protection2041
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
Phase 411 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
Phase 47 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugCompleted
Paliperidone
US-approved 2006 · Erzofri extended-release
Phase 37 trials
OwnerJohnson & Johnson
Protection2041
drugRecruiting
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 36 trials
OwnerAstraZeneca
Protection—
drugCompleted
Ziprasidone
US-approved 2001 · Geodon
Phase 36 trials
OwnerPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Protection—
drugCompleted
Lurasidone
US-approved 2010 · Latuda
Phase 34 trials
OwnerSumitomo Pharmaceuticals America
Protection2031
drugRecruiting
Clozapine
US-approved 1989 · Clozaril
Phase 42 trials
OwnerShanghai Mental Health Center
Protection2028
drugRecruiting
Lumateperone (Caplyta)
US-approved 2019 · CAPLYTA
Phase 31 trial
OwnerIntra-Cellular Therapies, Inc.
Protection2040
drugCompleted
Asenapine
US-approved 2009 · SAPHRIS
Phase 11 trial
OwnerOrganon and Co
Protection2033
drugCompleted
Iloperidone
US-approved 2009 · FANAPT
Phase 11 trial
OwnerVanda Pharmaceuticals
Protection2031
drugCompleted
Chlorpromazine
Pipeline · Phase 4
Phase 41 trial
OwnerMelbourne Health
Protection—

Market size

prevalence as a range, not a number